Ultragenyx Pharmaceutical enters settlement agreement with Navinta on Dojolvi patent litigation
RARE•Ultragenyx Pharmaceutical settled Dojolvi patent litigation with Navinta, which is licensed to market generic Dojolvi starting Jan. 1, 2033. The license period may extend to July 1, 2033, if pediatric exclusivity is granted; similar litigation against other Dojolvi ANDA filers remains pending.
1. Settlement terms
Ultragenyx Pharmaceutical entered a settlement agreement with Navinta in Dojolvi patent litigation. The SEC filing says Navinta is licensed to market generic Dojolvi from Jan. 1, 2033, with the license period potentially extending to July 1, 2033, if pediatric exclusivity is granted.
2. Other litigation pending
Similar patent litigation against other Dojolvi ANDA filers remains pending.
